CHRU Tours Performs 1st Implant of SynCardia’s Total Artificial Heart

Hospital is 30th in the World and 3rd in France to Become a SynCardia Certified Center

TUCSON, Ariz.--(BUSINESS WIRE)-- On April 1, Centre Hospitalier Universitaire et Régional de Tours (CHRU Tours) in France, led by Prof. Michel R. Aupart, performed its first implant of the SynCardia temporary Total Artificial Heart into a 44-year-old male with ischemic heart disease who had suffered a heart attack that caused both sides of his heart to fail.

“This patient was in desperate need of the Total Artificial Heart to bridge him to a heart transplant,” said Prof. Aupart. “It was urgent for us to complete the three phases of certification training so that we could save his life by performing our first implant of the Total Artificial Heart.”

The surgery was proctored by Prof. Pascal Leprince, an experienced Total Artificial Heart surgeon from Groupe hospitalier de la Pitié-Salpétrière in Paris, which has performed over 200 implants of the Total Artificial Heart, more than any other hospital in the world.

CHRU Tours averages 800 cardiac surgeries annually (of which 200 are pediatric cases) and performed 23 heart transplants in 2009. Over 14 years (1991-2005), CHRU Tours has achieved post-transplant survival rates of 91.3% at 1 year and 69.3% at 10 years.

CHRU Tours is the 30th hospital in the world and the third in France to become a SynCardia Certified Center.

About SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. There have been more than 850 implants of the Total Artificial Heart, accounting for more than 190 patient years of life on the device.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For additional information, please visit:
or follow SynCardia on Twitter – @SynCardia_News

Photos/Multimedia Gallery Available:


SynCardia Systems, Inc.
Don Isaacs
Vice President of Communications
Cell: 520-955-0660

KEYWORDS:   United States  Europe  North America  Arizona  France

INDUSTRY KEYWORDS:   Surgery  Technology  Hardware  Health  Cardiology  Hospitals  Medical Devices  Manufacturing  Engineering  General Health


SynCardia's temporary Total Artificial Heart (Photo: Business Wire)